aston.martin schreef op 22 mei 2013 13:55:
Seeking Alpha
AbbVie: Sliding Safely Instead Of Falling Off The Patent Cliff
May 22 2013, 01:23
...
A pipeline that is as strong as it comes
However, AbbVie's biggest strength is its pipeline. It has 10 development programs in Phase III clinical trials and plans to submit 15 candidates for approval between now and 2017. To its advantage, 30% of its development programs focus on biologics. FDA approval for the company's drug for Parkinson's disease, Duopa, is expected later this year.
In addition, AbbVie also plans to expand the use of Humira and seek approval for treatment of more diseases and is also working to boost its efforts on trials for finding a successor for Humira. The company announced recently of the extension of its clinical development collaboration for GLPG0634, the experimental program that it is working with Galapagos NV, to include Crohn's Disease. Galapagos is to fund a Phase 2 program of the drug and after completion AbbVie will $50 million and take over the development program beyond Phase 2.
As on March 30, 2013, the company had adequate cash (almost $7 billion) to fund development of its pipeline products. In addition it enjoys a healthy cash flow situation and a 20% profit margin.